Open AccessComparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer
Author(s) -
E.M. Schaffer,
E.M. Basch,
G.M. Schwab,
Antonia V. Bennett
Publication year - 2021
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/74s7-m110
Subject(s) - cabozantinib , prostate cancer , clinical endpoint , medicine , randomized controlled trial , oncology , cancer